Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2016, Article ID 9806515, 6 pages
http://dx.doi.org/10.1155/2016/9806515
Case Report

B-Cell Chronic Lymphocytic Leukemia with 11q22.3 Rearrangement in Patient with Chronic Myeloid Leukemia Treated with Imatinib

1Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Szamarzewskiego 82/84, 60-569 Poznan, Poland
2Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479 Poznan, Poland

Received 15 December 2015; Accepted 11 February 2016

Academic Editor: André Mégarbané

Copyright © 2016 Krzysztof Lewandowski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. V. Melo and D. J. Barnes, “Chronic myeloid leukaemia as a model of disease evolution in human cancer,” Nature Reviews Cancer, vol. 7, no. 6, pp. 441–453, 2007. View at Publisher · View at Google Scholar
  2. E. Ten Hacken and J. A. Burger, “Microenvironment interactions and B-cell receptor signaling in chronic lymphocytic leukemia: implications for disease pathogenesis and treatment,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1863, no. 3, pp. 401–413, 2016. View at Publisher · View at Google Scholar
  3. C. C. Laurie, C. A. Laurie, S. A. Smoley et al., “Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants,” Cancer Genetics, vol. 207, no. 1-2, pp. 19–30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Bhagavathi, V. Borromeo, H. Desai, and D. Crisan, “Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia,” Annals of Clinical and Laboratory Science, vol. 38, no. 4, pp. 405–409, 2008. View at Google Scholar · View at Scopus
  5. N. Gunnarsson, L. Stenke, M. Höglund et al., “Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era,” British Journal of Haematology, vol. 169, no. 5, pp. 683–688, 2015. View at Publisher · View at Google Scholar
  6. O. Benjamini, P. Jain, L. Trinh et al., “Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes,” Leukemia & Lymphoma, vol. 56, no. 6, pp. 1643–1650, 2015. View at Publisher · View at Google Scholar
  7. D. G. Peters, K. M. Klucher, R. C. R. Perlingeiro, S. K. Dessain, E. Y. Koh, and G. Q. Daley, “Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice,” Oncogene, vol. 20, no. 21, pp. 2636–2646, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Olcaydu, E. Rumi, A. Harutyunyan et al., “The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms,” Haematologica, vol. 96, no. 3, pp. 367–374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Björkholm, S. Y. Kristinsson, O. Landgren, and L. R. Goldin, “No familial aggregation in chronic myeloid leukemia.,” Blood, vol. 122, no. 3, pp. 460–461, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Li, J. Zhang, L. Wang et al., “MTHFR genetic polymorphisms may contribute to the risk of chronic myelogenous leukemia in adults: a meta-analysis of 12 genetic association studies,” Tumor Biology, vol. 35, no. 5, pp. 4233–4245, 2014. View at Publisher · View at Google Scholar
  11. S. L. Slager, N. E. Caporaso, S. de Sanjose, and L. R. Goldin, “Genetic susceptibility to chronic lymphocytic leukemia,” Seminars in Hematology, vol. 50, no. 4, pp. 296–302, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Ranjan, E. Penninga, A. M. Jelsig, H. C. Hasselbalch, and O. W. Bjerrum, “Inheritance of the chronic myeloproliferative neoplasms. A systematic review,” Clinical Genetics, vol. 83, no. 2, pp. 99–107, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Puiggros, G. Blanco, and B. Espinet, “Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go,” BioMed Research International, vol. 2014, Article ID 435983, 13 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. S. R. Gunn, A. R. Bolla, L. L. Barron et al., “Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene,” Leukemia Research, vol. 33, no. 9, pp. 1276–1281, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. E. Rodríguez, C. Robledo, J. L. García et al., “Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling,” Annals of Oncology, vol. 23, no. 8, pp. 2138–2146, 2012. View at Publisher · View at Google Scholar
  16. X. Lu, X. Wang, Y. Kim, R. Zhang, S. Li, and J.-Y. Lee, “Acquired genomic copy number changes in CML patients with the Philadelphia chromosome (Ph+),” Cancer Genetics, vol. 205, no. 10, pp. 513–518, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Luatti, F. Castagnetti, G. Marzocchi et al., “Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis,” Blood, vol. 120, no. 4, pp. 761–767, 2012. View at Publisher · View at Google Scholar
  18. D. A. Landau, S. L. Carter, P. Stojanov et al., “Evolution and impact of subclonal mutations in chronic lymphocytic leukemia,” Cell, vol. 152, no. 4, pp. 714–726, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Falisi, E. Novella, C. Visco et al., “B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities,” Hematological Oncology, vol. 32, no. 1, pp. 22–30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Perrotti, C. Jamieson, J. Goldman, and T. Skorski, “Chronic myeloid leukemia: mechanisms of blastic transformation,” Journal of Clinical Investigation, vol. 120, no. 7, pp. 2254–2264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Aljedai, A.-M. Buckle, P. Hiwarkar, and F. Syed, “Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL,” PLoS ONE, vol. 10, no. 4, Article ID e0123016, 2015. View at Publisher · View at Google Scholar
  22. B. Fattizzo, T. Radice, D. Cattaneo, M. Pomati, W. Barcellini, and A. Iurlo, “Three hematologic malignancies in the same patient: chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia,” Clinical Laboratory, vol. 60, no. 11, pp. 1929–1932, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Frederiksen, D. K. Farkas, C. F. Christiansen, H. C. Hasselbalch, and H. T. Sørensen, “Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study,” Blood, vol. 118, no. 25, pp. 6515–6520, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Tecchio, I. Nichele, G. Todeschini, G. Pizzolo, and A. Ambrosetti, “Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia: correspondence,” British Journal of Haematology, vol. 146, no. 2, pp. 222–223, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Serpa, I. Bendit, F. Seguro et al., “Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia,” Acta Haematologica, vol. 124, no. 2, pp. 105–109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Tung, Y. Shi, K. Wong et al., “PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia,” Blood, vol. 122, no. 6, pp. 969–980, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Veldurthy, M. Patz, S. Hagist et al., “The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes,” Blood, vol. 112, no. 4, pp. 1443–1452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. Y.-L. Lin and B. Roux, “Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases,” Journal of the American Chemical Society, vol. 135, no. 39, pp. 14741–14753, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. K. C. Lee, I. Ouwehand, A. L. Giannini, N. S. Thomas, N. J. Dibb, and M. J. Bijlmakers, “Lck is a key target of imatinib and dasatinib in T-cell activation,” Leukemia, vol. 24, no. 4, pp. 896–900, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. W. Harr, P. F. Caimi, K. S. McColl et al., “Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia,” Cell Death and Differentiation, vol. 17, no. 9, pp. 1381–1391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Nerreter, E. Distler, C. Köchel, H. Einsele, W. Herr, and R. Seggewiss-Bernhardt, “Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro,” Experimental Hematology, vol. 41, no. 7, pp. 604–614, 2013. View at Publisher · View at Google Scholar · View at Scopus